Vomiting evaluation

| Source | Examples |
|---|---|
| GI visceral afferents (vagal/sympathetic) | Gastric distension, irritation, duodenal stimuli |
| Extra-GI visceral afferents | Biliary system, peritoneum, pharynx, genitalia, heart (e.g., MI) |
| CNS/cortical afferents | Vestibular system, thalamus, cerebral cortex |
| Chemoreceptor trigger zone (CTZ) | Area postrema, floor of 4th ventricle — partially outside the blood-brain barrier; responds to drugs (morphine, digoxin, apomorphine, chemotherapy), toxins, metabolic derangements |
| Feature | Clinical significance |
|---|---|
| Timing/onset | Acute (<1 week) vs. chronic (>1 month) |
| Relationship to meals | Immediately post-prandial → gastric outlet obstruction or pyloric stenosis; early morning → pregnancy, raised ICP, uremia |
| Frequency and volume | Copious/frequent → obstruction |
| Effortless/projectile | Projectile without nausea → CNS etiology (raised ICP) |
| Relief with vomiting | Relieves pain in PUD and bowel obstruction; no relief in inflammatory conditions (cholecystitis, pancreatitis) |
| Vomitus Appearance | Suggested Diagnosis |
|---|---|
| Bright red blood | Peptic ulcer, gastritis, esophageal varices, Mallory-Weiss tear, Dieulafoy lesion, aortoenteric fistula |
| Coffee-ground | Any upper GI bleed; Hgb → hematin via gastric acid; also iron tablets, red wine |
| Undigested food | Gastric outlet obstruction, achalasia, esophageal stricture/atresia |
| Bilious (yellow-green) | Obstruction distal to ampulla of Vater |
| Feculent (brown, fecal odor) | Advanced low small bowel or large bowel obstruction |
| True feces | Gastrocolic fistula |
| Age | Priority Diagnoses |
|---|---|
| Newborn | Esophageal/intestinal atresia, malrotation ± volvulus, Hirschsprung's, metabolic disorders, sepsis |
| Infant (<12 mo) | Pyloric stenosis, intussusception, GERD, UTI, meningitis |
| Child (>12 mo) | Gastroenteritis, intussusception, migraine, appendicitis, intracranial mass |
Bilious or bloody vomitus, hematochezia, or significant abdominal pain should trigger concern for diagnoses beyond simple viral gastroenteritis. — Tintinalli's Emergency Medicine
| System | Finding | Suggested Diagnosis |
|---|---|---|
| General | Poor skin turgor, dry mucous membranes | Dehydration |
| Vital signs | Fever | Gastroenteritis, cholecystitis, appendicitis, peritonitis |
| Vital signs | Tachycardia + orthostatic changes | Dehydration/volume depletion |
| Eyes | Nystagmus | Labyrinthitis, vertebrobasilar insufficiency, cerebellar infarct/bleed, drug intoxication |
| Eyes | Papilledema | Raised ICP (CNS tumor, bleed) |
| Neck | Goiter | Thyroid disease |
| Lungs | Rales | Pneumonia |
| Abdomen | Distension, high-pitched bowel sounds | Obstruction |
| Abdomen | RUQ tenderness + Murphy's sign | Cholecystitis |
| Abdomen | Rigidity/guarding | Peritonitis, perforation |
| Oral | Loss of dental enamel | Bulimia nervosa |
| Test | Indication |
|---|---|
| BMP/electrolytes, BUN, Cr | Assess dehydration, metabolic alkalosis, renal failure |
| CBC | Infection, anemia |
| LFTs, lipase | Biliary/pancreatic disease |
| Urine hCG | Any woman of reproductive age |
| Urinalysis | UTI, renal disease |
| Blood glucose | DKA |
| Upright CXR / AXR | Free air (perforation), obstruction (air-fluid levels), pneumonia |
| CT abdomen/pelvis | Obstruction, appendicitis, pancreatitis, mass |
| Head CT / MRI | Suspected CNS etiology |
| Upper endoscopy | Chronic vomiting, hematemesis, suspected mucosal disease |
| Gastric emptying scan | Suspected gastroparesis |
| Drug | Class | Mechanism | Dose | Notes |
|---|---|---|---|---|
| Ondansetron | 5-HT3 antagonist | CTZ + vagal GI terminals | 4–8 mg IV/PO | First-line; generally well-tolerated |
| Metoclopramide | D2/5-HT2 antagonist | CTZ + gastric motility | 10–20 mg IM/IV q6h | Risk of tardive dyskinesia (black box) |
| Prochlorperazine | D1/D2 antagonist | CTZ | 5–10 mg IM/PO; 25 mg PR | Extrapyramidal effects |
| Droperidol / Haloperidol | D2 antagonist | CTZ | 1.25 / 5 mg IV | QT prolongation monitoring |
| Promethazine | H1/muscarinic antagonist | Vestibular nucleus | 12.5–25 mg IM/IV | Sedating; IV route → tissue necrosis risk |
| Dimenhydrinate | H1 antagonist | Vestibular nucleus | 25–50 mg PO/IV | Motion sickness |
| Dexamethasone | Corticosteroid | CNS/undefined | 4–8 mg IV | PONV, chemotherapy-induced |
| Aprepitant | NK1 antagonist | Substance P/CTZ | 40–125 mg PO | PONV, chemotherapy |
| Scopolamine | Muscarinic antagonist | Vestibular nucleus | 1.5 mg patch | Motion sickness |